Home » Drug Information » FDA Approved Drugs » 1998
Medical Areas: Neurology | Family Medicine
View By:YearCompanyConditionsTherapeutic AreasDrug Names
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Approval Status: Approved February 1998
Treatment Area: acute migraine
Amerge (naratriptan hydrochloride) Tablets have been approved
for the treatment of acute migraine. Amerge is a selective 5-HT
agonist designed specifically to treat migraine attacks. In
clinical trials, 60-66% of patients with moderate to severe
headache responded to Amerge 2.5 mg within four hours. Of the
patients who had relief with the initial dose, 72-81% did not have
recurrence of headache within 24 hours.
Amerge is indicated for the acute treatment of migraine attacks
with or without aura in adults. Amerge is not intended to prevent
or reduce the number of migraine attacks nor is it for use in the
treatment of cluster headache, or management of basilar or
The only reported side effect with a greater than 2% incidence
was nausea 5%.